Biocept Inc. (BIOC)

1.51 -0.03 (-1.948%)

IEX Real-Time Price

9:55:50 AM EST.

NASDAQ Capital Market : Healthcare

Prev Close 1.54

Price Open 1.52

Volume: 1,323

Avg Volume: 224,233

Market Cap: 6.13M

P/E Ratio -0.11

52 Wk Range 1.46-36



BIOC Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
1.73M
325,249
1.50
18.85%

2018-09-28
1.73M
255,284
1.48
14.79%

2018-09-14
1.73M
218,826
1.25
12.68%

2018-08-31
1.73M
283,881
1.47
16.45%




BIOC Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-14
Q2 2018
AMC
-3.30 (1)
-2.70
0.60

2018-05-15
Q1 2018
AMC
-0.07 (1)
-0.11
-0.04

2018-05-10
Q1 2018
N/A
0.00 (0)
0.00
0.00

2018-03-28
Q4 2017
AMC
-0.19 (1)
-0.18
0.01

News

Biocept's (BIOC) CEO Michael Nall on Q3 2018 Results - Earnings Call Transcript (2018-11-13 20:55 SeekingAlpha)

Biocept, Inc. (BIOC) Q3 2018 Results Earnings Conference Call November 13, 2018, 4:30 PM ET Executives Jody Cain - LHA, IR Michael Nall - President and CEO Tim Kennedy - Senior Vice President, Operations and CFO Edwin Hendrick - Senior Vice President and CCO Analysts Laur…

 


Statistics

Shares Outstanding: 4.06M

Top 15 Institution Percent: 145.20

Price To Sales: 2.49

Price To Book: 2.47

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -209.18

Return On Equity: -486.29

Profit Margin: N/A

Price History

Beta: 2.03

50-day Moving Avg: 2.43

200-day Moving Avg: 5.68

YTD Change: -92.67

5-day Change: -14.92

1-month Change: -31.86

3-month Change: -49.67

6-month Change: -71.79

1-year Change: -91.97

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Biocept Inc.

Exchange: NASDAQ Capital Market

Industry: Medical Diagnostics & Research

Sector: Healthcare

Website: http://www.biocept.com

Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample.